AKT1 and neoplasm: To enable prospective screening for the low prevalence AKT1 E17K mutation, we have developed and validated a competitive allele-specific TaqMan® PCR (castPCRTM) assay for mutation detection in formalin-fixed paraffin-embedded (FFPE) tumor tissue.